Exploring SKYRIZI's Exceptional Growth: Revenue and Market Expansion Analysis

SKYRIZI, AbbVie's IL-23 inhibitor, has achieved blockbuster status with global sales reaching $11.7 billion in 2024 (51% YoY growth). The drug is expanding across multiple indications including psoriasis, psoriatic arthritis, and IBD, with strong gastroenterology uptake and favorable dosing schedules. AbbVie forecasts combined revenues for SKYRIZI and Rinvoq to exceed $31 billion annually by 2027, positioning SKYRIZI as the largest contributor to its $26.7 billion immunology portfolio.